Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy

Inal, Jameel (2020) Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy. Clinical science, 134 (12). pp. 1301-1304. ISSN 1470-8736

Preview

Text cs-134-cs20200623.pdf - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives 4.0. Download (427kB) | Preview

Abstract / Description

The novel strain of coronavirus that appeared in 2019, SARS-CoV-2, is the causative agent of severe respiratory disease, COVID-19, and the ongoing pandemic. As for SARS-CoV that caused the SARS 2003 epidemic, the receptor on host cells that promotes uptake, through attachment of the spike (S) protein of the virus, is angiotensin-converting enzyme 2 (ACE2). In a recent article published by Batlle et al. (Clin. Sci. (Lond.) (2020) 134, 543-545) it was suggested that soluble recombinant ACE2 could be used as a novel biological therapeutic to intercept the virus, limiting the progression of infection and reducing lung injury. Another way, discussed here, to capture SARS-CoV-2, as an adjunct or alternative, would be to use ACE2+-small extracellular vesicles (sEVs). A competitive inhibition therapy could therefore be developed, using sEVs from engineered mesenchymal stromal/stem cells (MSCs), overexpressing ACE2.

Item Type:	Article
Additional Information:	** From PubMed via Jisc Publications Router [Abstract copyright: © 2020 The Author(s).]
Uncontrolled Keywords:	ARDS, COVID-19, Extracellular Vesicles, SARS-CoV-2, competitive inhibition therapy
Subjects:	500 Natural Sciences and Mathematics > 570 Life sciences; biology 600 Technology > 610 Medicine & health
Department:	School of Human Sciences
SWORD Depositor:	Pub Router
Depositing User:	Pub Router
Date Deposited:	10 Jul 2020 13:28
Last Modified:	29 Mar 2021 13:58
URI:	https://repository.londonmet.ac.uk/id/eprint/5831

Downloads

Actions (login required)

View Item